Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized comparison of HAA versus DA induction therapy in adult acute myeloid leukemia
ChiCTR1800019306Phase 3Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of homoharringtonine, cytarabine, aclarubicin and daunorubicin in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission rate. Started Nov 2018; status: recruiting.
02
Drugs
homoharringtoninecytarabineaclarubicindaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800019306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019306.